Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent

Thrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this conditi...

Descripción completa

Detalles Bibliográficos
Autores: Rodriguez-Mori, Juan E., Mego-Arellan, Denese C., Sumire-Umeres, Julia, Asato-Higa, Carmen, Rodríguez-Mori, Juan E.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:Perú
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Idioma:español
OAI Identifier:oai:amp.cmp.org.pe:article/1056
Acceso en línea:https://amp.cmp.org.pe/index.php/AMP/article/view/1056
Access Level:acceso abierto
Palabra clave:Microangiopatías trombóticas
Tacrolimus
Trasplante renal
Thrombotic microangiopathies
Kidney transplantation
Descripción
Sumario:Thrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this condition presents in non-complete forms, which makes diagnosis difficult, and irreversible lesions may supervene. This case features the presence of a viral infection, and data suggesting rejection with the concomitant tacrolimus use. Therapy includes plasmapheresis and the use of monoclonal antibodies such as eculizumab. Nonetheless, in this particular case suspending therapy or switching from tacrolimus to another agent were good cost-effective measures.